



Universiteit
Leiden
The Netherlands

Differences and similarities of autoantibody-positive and autoantibody-negative rheumatoid arthritis during the disease course: on our way to personalized medicine

Matthijssen, X.M.E.

Citation


Matthijssen, X. M. E. (2022, June 21). *Differences and similarities of autoantibody-positive and autoantibody-negative rheumatoid arthritis during the disease course: on our way to personalized medicine*. Retrieved from <https://hdl.handle.net/1887/3421332>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3421332>

Note: To cite this publication please use the final published version (if applicable).



CHAPTER

6

Differing time orders of inflammation decrease between ACPA-subsets in RA-patients suggest differences in underlying inflammatory pathways

Xanthe M.E. Matthijssen¹

E. Niemantsverdriet¹

S. le Cessie^{2,3}

Annette H.M. van der Helm-van Mil^{1,4}

1. Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
2. Department of Epidemiology, Leiden University Medical Center, Leiden, Netherlands
3. Departments of Biomedical Data Science, Leiden University Medical Center, Leiden, Netherlands
4. Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands

ABSTRACT

Objectives

Advanced imaging modalities have shown that not only joints but also bones and tendon sheaths can be inflamed at diagnosis of rheumatoid arthritis. We aimed to better understand the time order in which the inflamed tissues respond to DMARD-treatment. Also, because ACPA-status may reflect a different pathophysiology, differences in time order of inflammation decrease were hypothesized between these disease types.

Methods

216 consecutive patients presenting with rheumatoid (n=176) or undifferentiated arthritis (N=40), who all started with csDMARD-treatment, were studied. 1.5T contrast-enhanced hand and foot MRIs were performed before treatment and after 4, 12 and 24-months. Cross-lagged models evaluated the influence of two time-patterns: a simultaneous pattern ("change in one inflammatory feature associated with change in another feature") and a subsequent pattern ("change in one inflammatory feature preceded change in another feature"). ACPA-stratification was performed.

Results

The median symptom duration at presentation was 13 weeks. 44% of patients was ACPA-positive.

All pairs of inflammatory features decreased simultaneously in all time-intervals (0–4/4–12/12–24m; $p < 0.05$). Moreover, time orders were identified: synovitis decrease preceded tenosynovitis decrease (0–4m->4–12m; $p = 0.02$ & 4–12m->12–24m; $p = 0.03$). Largely similar results were obtained in both ACPA-subgroups. Additionally, in ACPA-positive but not ACPA-negative patients, synovitis decrease preceded osteitis decrease (4–12m->12–24m; $p = 0.002$).

Conclusion

This study increased the understanding of the response to treatment on tissue level. Additional to simultaneous decrease of inflammation, synovitis decrease preceded tenosynovitis decrease. Differences in time order of inflammation decrease between ACPA-subgroups suggest differences in underlying inflammatory pathways.

KEY MESSAGES

- This study increased the understanding of the response to treatment on tissue level.
- Additional to simultaneous decrease of inflammation, synovitis decrease preceded tenosynovitis decrease.
- Differences in time order of inflammation decrease between ACPA-subgroups suggest differences in underlying inflammatory pathways.

BACKGROUND

During the last decennium advanced imaging modalities, including MRI, have refined our understanding of the tissues involved in rheumatoid arthritis (RA) and have shown that not only joints but also bones and adjoining synovial tendon sheaths of small joints are frequently inflamed.(1,2) These tissues are distinct anatomical structures but synovitis, osteitis and tenosynovitis frequently co-occur at diagnosis.(1,3) Remarkably, previous research suggested time-orders in inflammation development of these tissues during RA-development.(2,4) If time-order are present in developing RA, we assume that there are also time-orders in inflamed tissue in decrease of inflammation. However, little is known about the mutual influence of inflammation of these tissues when inflammation is resolving due to treatment.

Some studies investigated inflammation decrease in joints, bones and tendon sheaths after treatment in early RA.(5-7) However, they did not determine whether inflammation decrease is simultaneous in all tissues or whether sequences also play a role, as time-orders were not studied. Also, anti-citrullinated protein antibody (ACPA)-subgroups were not studied separately, while these are considered different disease types with differences in underlying pathophysiology.(8-10) Consequently, differences in time-order of inflammation decrease in response to treatment can be expected but, to our knowledge, this has not been explored yet.

Our aim was to achieve a better understanding of the time-orders in which the different inflamed tissues (joint, bone, tendon sheath) respond to DMARD-treatment, and whether this differs between ACPA-subgroups. In the Leiden Early Arthritis inception cohort (EAC), MRIs of undifferentiated arthritis (UA) and RA-patients were performed at presentation (before DMARD-initiation) and after 4, 12 and 24-months. This allowed for differentiation between simultaneous and subsequent patterns of inflammation decrease of joint, bone and tendon sheath after DMARD-initiation in 3 consecutive time periods.

METHODS

Patients

Since 1993, consecutive early arthritis patients (<2years symptom duration) were included in the Leiden EAC. This inception cohort is extensively described elsewhere.(11) In short, patient-characteristics, disease activity and laboratory parameters were obtained at baseline, 4-months, 12-months and yearly thereafter. From August-2010 until February-2015, MRIs were performed at baseline and 4, 12 and 24-months when

the initial clinical diagnosis was UA or RA.

Treatment

Patients were treated in routine care and in line with (inter-)national guidelines.(12) Medication data were extracted from the hospital patient information system and quality controlled. Doctors and patients were blinded for MRI-data.

Patient selection

From all patients with an initial clinical diagnosis of RA or UA were consecutively included from August-2010 until February-2015 (n=655) patients starting with DMARDS (including glucocorticoids) within 100-days after the first rheumatology outpatient clinic visit were selected (n=376). 160 patients did not undergo repeated MRIs (mostly for logistical reasons), resulting in 216 patients that were studied. Baseline characteristics of patients who started early with DMARD-treatment and who did and did not have repeated MRIs were not statistically significantly different (Supplementary1).

MRI

MRI was performed at baseline (before DMARD-initiation) and 4, 12 and 24-months. Metacarpophalangeal (MCP(2-5)), wrist and metatarsophalangeal (MTP(1-5))-joints on the most painful side at baseline (dominant side in case of symmetric symptoms) were imaged with 1.5TMRI (GE,Wisconsin,USA). Follow-up MRIs were performed at the side of the baseline MRI. MRIs were scored for synovitis and osteitis in line with RAMRIS and tenosynovitis as described by Haavardsholm, by one reader, with known time-order, blinded for any clinical data.(13,14) Intrareader reliability was excellent (ICC0.98; Supplementary2). Scores were summed per inflammatory feature per patient. Supplementary3 provides a detailed scan and scoring protocol.

Statistical analysis

Data of three time-intervals (0-4/4-12/12-24-months) were studied with cross-lagged models.(15) Cross-lagged models can evaluate the influence of two time-patterns in one model: 1) a simultaneous pattern ("change in one inflammatory feature is associated with change in another feature") and 2) a subsequent pattern ("change in one inflammatory feature precedes change in another feature") as is shown in Supplementary4. Despite these benefits, these models are infrequently used in rheumatology research and most often employed in psychology.(15) Further explanation is presented in Supplementary5.

Because of skewness, MRI-variables were log-transformed, after addition of 1 point to facilitate transformation of zeroes. This and the complex structure of the cross-lagged

models results in estimates that are not easily interpreted. We therefore expressed them in standardized regression coefficients and correlations. Standardized regression coefficients are independent of scale and lie between -1 and 1. A value of -1 (negative) or 1 (positive association) indicates full explanation of the dependent variable by the independent variable and a value of 0 indicates no association. Congruently, correlations lie between -1 and 1, and 0 indicates no association.

MRIs at 4-months, 12-months and 24-months were missing in 11%, 20% and 47%, respectively (23, 44 and 102 MRIs, respectively). We assumed missing at random (MAR), not missing completely at random, because patients with a less severe disease presumably had less follow-up with MRI. MAR implies that missingness, not explained by variables included in the model, is random. Since disease activity is correlated with MRI-inflammation,(16) which is included in the model, and ACPA-stratification was performed, no further variables associated with missingness were included in the models to achieve MAR. Also, cross-lagged models were fitted with full-information likelihood, appropriate for MAR.(17)

Because ACPA-status may reflect a different pathophysiology, analyses were repeated stratified for ACPA-status (anti-CCP2).

Additional analyses

As sensitivity analyses, analyses were repeated in the subgroup of RA-patients (clinical diagnosis plus fulfilment of 1987- or 2010-criteria <1-year). In addition, analyses were repeated in patients that started DMARD-treatment within 31-days.

To assess the influence of initial treatment, sensitivity analyses were performed in patients starting methotrexate as first therapy (as this was the most frequently used first-line DMARD). In addition, analyses were repeated in patients starting methotrexate without corticosteroid bridging.

To assess natural course, decrease of MRI-inflammation of UA and RA-patients that, in contrast to the guidelines,(12) did never receive DMARD-treatment and were therefore excluded, was presented.

R3.6.1, RStudio1.2.5001, Onyx 1.0-101 and OpenMx 2.14.11 were used (Supplementary5). Two-sided p-values <0.05 were considered significant.

RESULTS

Baseline characteristics

Patient baseline characteristics are shown in Supplementary6: mean age was 58, 62% female, 44% ACPA-positive, 74% received initial methotrexate and the remaining patients started with other csDMARDs. The median symptom duration at presentation was 13 weeks and the median time to DMARD-start 2.4 weeks. 82% classified as RA (Supplementary7).

Simultaneous and subsequent patterns


Plotting the MRI-data over time revealed that synovitis, osteitis and tenosynovitis decreased during follow-up (Figure 1). For osteitis, this decrease manifested predominantly in decreasing interquartile ranges.

To assess the influence of both the simultaneous and subsequent pattern in one model, cross-lagged models were used. With respect to the simultaneous patterns, all pairs of inflammatory features showed significant simultaneous decrease in all time-intervals (0-4/4-12/12-24m (months);Table 1).

In addition to simultaneous decrease, time-orders were identified (Table 1). Predominantly, synovitis decrease preceded tenosynovitis decrease. Synovitis decrease 0-4m preceded tenosynovitis decrease 4-12m (standardized regression coefficient (β) and 95% confidence interval: 0.28(0.04;0.53); Figure 1) and synovitis decrease 4-12m preceded tenosynovitis decrease 12-24m (β =0.27(0.04;0.50)).

Moreover, early tenosynovitis decrease (0-4m) significantly preceded osteitis decrease 4-12m with a smaller effect size (β =0.15(0.00;0.31)). However, 'late' tenosynovitis decrease (4-12m) did not precede osteitis decrease 12-24m (β =0.01(-0.13;0.14)), together this suggests that this finding with a smaller effect size is less robust than the other findings.

Figure 1: Individual courses of synovitis, tenosynovitis and osteitis in all patients studied (I) and an example of serial MRI of the MCP-joints of an individual patient (II) at (A) baseline, (B) 4 months, (C) 12 months and (D) 24 months



Legend: Part I: Lines represent individual patient trajectories. The bold line represents the median and the grey area the interquartile range. For readability, summed RAMRIS scores above 15 were omitted from the graph; Part II: These MRIs show synovitis (closed arrows) decrease between 0 and 4 months preceding tenosynovitis (open arrows) decrease between 4 and 12 months

Table 1: Estimates of simultaneous and subsequent change of three inflammatory features

Simultaneous change	All patients	ACPA-positive	ACPA-negative
Synovitis with Tenosynovitis			
0-4m	0.20 (0.14;0.26)*	0.21 (0.12;0.31)*	0.20 (0.12;0.28)*
4-12m	0.20 (0.13;0.28)*	0.19 (0.09;0.30)*	0.22 (0.11;0.33)*
12-24m	0.29 (0.20;0.38)*	0.27 (0.15;0.39)*	0.31 (0.18;0.45)*
Synovitis with Osteitis			
0-4m	0.13 (0.08;0.19)*	0.19 (0.10;0.28)*	0.10 (0.02;0.17)*
4-12m	0.16 (0.09;0.22)*	0.14 (0.05;0.23)*	0.17 (0.07;0.26)*
12-24m	0.11 (0.04;0.19)*	0.20 (0.10;0.30)*	0.00 (-0.09;0.09)
Tenosynovitis with Osteitis			
0-4m	0.07 (0.01;0.14)*	0.06 (-0.03;0.16)	0.08 (-0.01;0.17)
4-12m	0.13 (0.05;0.22)*	0.11 (0.01;0.22)*	0.21 (0.09;0.33)*
12-24m	0.12 (0.04;0.21)*	0.14 (0.03;0.25)*	0.07 (-0.05;0.19)
Subsequent change	All patients	ACPA-positive	ACPA-negative
Synovitis precedes Tenosynovitis			
0-4m -> 4-12m	0.28 (0.04;0.53)*	0.23 (-0.11;0.56)	0.35 (0.01;0.68)*
4-12m -> 12-24m	0.27 (0.04;0.50)*	0.38 (0.10;0.66)*	0.18 (-0.17;0.54)
Tenosynovitis precedes Synovitis			
0-4m -> 4-12m	0.04 (-0.11;0.19)	0.08 (-0.13;0.29)	0.02 (-0.20;0.23)
4-12m -> 12-24m	0.04 (-0.13;0.20)	0.08 (-0.18;0.34)	-0.03 (-0.23;0.17)
Synovitis precedes Osteitis			
0-4m -> 4-12m	0.11 (-0.09;0.32)	0.13 (-0.16;0.42)	0.07 (-0.22;0.36)
4-12m -> 12-24m	0.09 (-0.09;0.27)	0.40 (0.17;0.64)*	-0.23 (-0.45;-0.01)*
Osteitis precedes Synovitis			
0-4m -> 4-12m	0.12 (-0.04;0.27)	0.08 (-0.15;0.32)	0.13 (-0.08;0.33)
4-12m -> 12-24m	0.17 (-0.05;0.38)	0.24 (-0.05;0.53)	0.16 (-0.14;0.47)
Tenosynovitis precedes Osteitis			
0-4m -> 4-12m	0.15 (0.00;0.31)*	0.04 (-0.18;0.25)	0.19 (-0.02;0.40)
4-12m -> 12-24m	0.01 (-0.13;0.14)	0.12 (-0.11;0.35)	-0.11 (-0.27;0.04)
Osteitis precedes Tenosynovitis			
0-4m -> 4-12m	-0.02 (-0.23;0.19)	-0.02 (-0.31;0.26)	-0.04 (-0.33;0.25)
4-12m -> 12-24m	0.14 (-0.10;0.39)	0.23 (-0.07;0.54)	0.09 (-0.30;0.49)

Legend: Estimates of simultaneous change represent correlation of proportion of change of two inflammatory features that is not explained by the subsequent pattern and previous values of those inflammatory features, with 95% confidence intervals. Estimates of subsequent change represent standardized regression coefficients of change of one inflammatory feature to subsequent change in another inflammatory feature, corrected for the simultaneous pattern and previous values of those inflammatory features, with 95% confidence intervals. Standardized regression coefficients are independent of scale and lie between -1 and 1. A value of -1 or 1 indicates full explanation of change in one inflammatory feature by change in the previous period of another inflammatory feature and a value of 0 indicates no explanation. Values -1 and 0 (negative estimate) indicate that a decrease in the first period is associated with less decrease in the subsequent period, in addition values between 0 and 1 indicate that a decrease in the first period is associated with more decrease in the subsequent period. *: significant estimate (p<0.05)

ACPA-stratification

Simultaneous decrease was present in both ACPA-subsets and similar to that described above (Table 1).

Also in both ACPA-subsets synovitis decrease preceded tenosynovitis decrease with similar estimates, albeit not always reaching statistical significance which may be due to the smaller sample size (Table 1).

In addition, an ACPA-specific time-order was identified: In ACPA-positive patients synovitis decrease 4-12m preceded osteitis decrease 12-24m ($\beta=0.40(0.17;0.64)$). This was significantly different from ACPA-negative patients ($p<0.001$), in which the estimate was in the opposite direction ($\beta=-0.23(-0.45;-0.01)$).

Additional analyses

All analyses were repeated in RA-patients ($n=176$) and in patients that started DMARD-treatment within 31-days ($n=153$); similar results were obtained (Supplementary8&9). In patients starting with methotrexate, similar results were obtained, also when excluding patients receiving corticosteroid bridging (Supplementary10).

Finally the natural course of subgroup of patients, UA and RA-patients that did never receive DMARD-treatment (and were therefore excluded from the analyses), was plotted and showed little decrease (Supplementary11).

DISCUSSION

We aimed to better understand the time-order of the response of different inflamed tissues (joint, bones and adjoining tendon sheaths of small joints) to DMARD-treatment. Using cross-lagged models, we found that the inflammatory features not only decrease simultaneously but also that decrease in synovitis preceded decrease in tenosynovitis.

Since the last decade advanced imaging studies have revealed that inflammation in RA is not only synovitis but also comprises osteitis and tenosynovitis. Information on time-orders of inflammation decrease provide insight in the sensitivity to treatment of these different inflamed tissues. Previous research on RA-development suggested that tenosynovitis presents early in the pre-arthritis phase and is followed by synovitis. (2,4) Our research suggests that a decrease of synovitis is followed by a decrease in tenosynovitis; these findings together possibly suggest that inflammation that comes the earliest (e.g. tenosynovitis), resolves slower. Further research is needed to elucidate

the molecular mechanism of this relationship.

Previous studies have shown that osteitis is more often present in ACPA-positive RA and is strongly associated with erosion development and is therefore an important feature in ACPA-positive RA.(18,19) In our data ACPA-positive patients at baseline had slightly higher osteitis scores (Supplementary7). Moreover our data further supports that osteitis is an important feature in ACPA-positive RA by showing that synovitis decrease 4-12m preceded subsequent osteitis decrease 12-24m only in ACPA-positive patients. In contrast to this late subsequent decrease, no significant effect of synovitis decrease 0-4m on osteitis decrease 4-12m was observed in ACPA-positive patients. This could indicate that suppression of inflammation in ACPA-positive patients affects synovitis first, but that a prolonged suppression of inflammation is needed to attain osteitis decrease in these patients.

In ACPA-negative patients, the effect of synovitis decrease 4-12m on subsequent osteitis decrease 12-24m was negative, meaning that more decrease in synovitis 4-12m is associated with less decrease in osteitis 12-24m. In addition, synovitis and osteitis showed high simultaneous decrease in 4-12m. Together, this can imply that more inflammation suppression and resulting synovitis and osteitis decrease between 4-12m results in a plateau in osteitis 12-24m in ACPA-negative patients.

To our knowledge, our study is the first to show a differential disease course after treatment at the tissue level in ACPA-subgroups. While this might not have any direct clinical implications, important improvements of treatment are often fuelled by a better understanding of the pathophysiology of disease. By increasing knowledge of the effect of treatment of RA on tissue level, stratified for autoantibody-status, we ultimately hope to contribute to improved treatment in RA, that might differ between ACPA-subgroups.

This study is, to our knowledge, the first observational MRI-study in DMARD-naïve patients that includes both early (<6m) and late (>1y) MRIs. Timing of MRIs was set at fixed timepoints after inclusion and therefore not dependent on date of DMARD-initiation. Reassuringly, in patients treated within 31-days, therefore having similar time periods between treatment and MRIs, results were comparable. The second MRI was made after 4-months, the time when the efficacy of the initiated conventional DMARD is generally evaluated. Therefore, we could not perform analyses on very fast inflammation decrease due to corticosteroids. This was beyond the scope of this study. Limitations include that MRI scans were scored by a single reader. Encouragingly, intrareader reliability was excellent (Supplementary2). Moreover, two different MRI-protocols were used for the MTP-joints. Reassuringly, previous studies showed that

these protocols perform equally in depicting osteitis and sensitivity analyses omitting the MTPs showed similar results (Supplementary3).(20) The number of patients with missing MRI increased over time, especially in patients with less severe disease, resulting in missingness depending on measured covariates (MAR). Hence, we used statistical techniques appropriate for MAR.

Numbers became smaller after ACPA-stratification. Therefore, main analyses were performed in all patients with both definite RA and UA that required, according to the rheumatologist, early DMARD-treatment. Several sensitivity analyses were performed to assess robustness of results, all showing similar results. Additionally, data were insufficient to perform analyses on joint level. Therefore, validation of our findings in larger longitudinal MRI-studies in both ACPA-subgroups is warranted.

Our analyses were conducted in longitudinal cohort data, not in randomized placebo controlled trial data. While treatment was not randomized, it was protocolized, indicated by >80% of RA-patients starting with initial methotrexate. Analyses in patients starting with methotrexate showed similar results. Analyses for patients that started with other conventional first-line DMARDs were not performed due to low numbers. Biologicals were only allowed if patients failed on ≥ 2 conventional DMARDs and biologic use during the studies 2-year follow-up was infrequent (3% in ACPA-negative and 14% in ACPA-positive patients at year 2), impeding sensitivity analyses in this group. Therefore, whether different DMARDs (including biologicals) have differential influence on the tissue level remains an interesting question for future research.

Importantly both patients and rheumatologists were blinded for MRI-data, limiting the influence of MRI-inflammation on treatment decisions. Still, inflammation decrease can be partly due to natural course or bias due to reading MRIs in chronological order. To evaluate this, MRIs of UA and RA-patients that, in contrast to the guidelines,(12) did never receive DMARD-treatment, were scored simultaneously with the MRIs of our study, blinded for clinical data. This revealed that MRI-inflammation decreased little in untreated patients (Supplementary11). Therefore, the decrease observed in the treated patients most likely represents a treatment-effect.

In conclusion, this study increased the understanding of treatment-response on tissue level. In addition to simultaneous decrease of synovitis, osteitis and tenosynovitis, time-orders of response in inflamed tissues were identified, that were partly different in the ACPA-subgroups. This suggests different inflammatory pathways underlie MRI-inflammation in ACPA-positive and ACPA-negative disease.

REFERENCES

- Krabben A, Stomp W, Huizinga TW, van der Heijde D, Bloem JL, Reijnen M, et al. Concordance between inflammation at physical examination and on MRI in patients with early arthritis. *Annals of the rheumatic diseases*. 2015;74(3):506-12.
- Ten Brinck RM, van Steenbergen HW, van der Helm-van Mil AHM. Sequence of joint tissue inflammation during rheumatoid arthritis development. *Arthritis research & therapy*. 2018;20(1):260.
- Werner D, Simon D, Englbrecht M, Stemmler F, Simon C, Berlin A, et al. Early Changes of the Cortical Micro-Channel System in the Bare Area of the Joints of Patients With Rheumatoid Arthritis. *Arthritis & Rheumatology*. 2017;69(8):1580-7.
- Hayer S, Redlich K, Korb A, Hermann S, Smolen J, Schett G. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. *Arthritis and rheumatism*. 2007;56(1):79-88.
- Zhang H, Xu H, Chen S, Mao X. The application value of MRI in the diagnosis of subclinical inflammation in patients with rheumatoid arthritis in remission. *Journal of orthopaedic surgery and research*. 2018;13(1):164.
- Sundin U, Aga A-B, Skare Ø, Nordberg LB, Uhlig T, Hammer HB, et al. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. *Rheumatology (Oxford, England)*. 2020:kez674.
- Haavardsholm EA, Boyesen P, Ostergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. *Annals of the rheumatic diseases*. 2008;67(6):794-800.
- Matthijssen XME, Huizinga TW, Niemantsverdriet E, van der Helm-van Mil AHM. Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study. *Arthritis Rheumatology* 2019;71 (suppl 10).
- van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. *Arthritis research & therapy*. 2005;7(5):R949-58.
- Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. *Arthritis research & therapy*. 2006;8(4):R133.
- van Aken J, van Bilsen JH, Allaart CF, Huizinga TW, Breedveld FC. The Leiden Early Arthritis Clinic. *Clinical and experimental rheumatology*. 2003;21(5 Suppl 31):S100-5.
- Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. *Annals of the rheumatic diseases*. 2017;76(6):948-59.
- Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. *The Journal of rheumatology*. 2003;30(6):1385-6.
- Haavardsholm EA, Ostergaard M, Ejbjerg BJ, Kvan NP, Kvien TK. Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study. *Annals of the rheumatic diseases*. 2007;66(9):1216-20.
- Selig J, Little T. Autoregressive and cross-lagged panel analysis for longitudinal data. 2012. p. 265-78.
- Emery P, van der Heijde D, Ostergaard M, Conaghan PG, Genovese MC, Keystone EC, et al. Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. *Annals of the rheumatic diseases*. 2011;70(12):2126-30.
- Enders CK, Bandalos DL. The Relative Performance of Full Information Maximum Likelihood Estimation for Missing Data in Structural Equation Models. *Structural Equation Modeling: A Multidisciplinary Journal*. 2001;8(3):430-57.
- Boeters DM, Nieuwenhuis WP, Verheul MK, Newsum EC, Reijnen M, Toes REM, et al. MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. *Arthritis research & therapy*. 2016;18:179-.
- Nieuwenhuis WP, van Steenbergen HW, Stomp W, Stijnen T, Huizinga TW, Bloem JL, et al. The Course of Bone Marrow Edema

in Early Undifferentiated Arthritis and Rheumatoid Arthritis: A Longitudinal Magnetic Resonance Imaging Study at Bone Level. *Arthritis & rheumatology* (Hoboken, NJ). 2016;68(5):1080-8.

20. Bloem JL, Reijnierse M, Huizinga TWJ, van der Helm-van Mil AHM. MR signal intensity: staying on the bright side in MR image interpretation. *RMD open*. 2018;4(1):e000728.